Acadia Healthcare (NASDAQ:ACHC) Issues Quarterly Earnings Results, Beats Expectations By $0.03 EPS

Acadia Healthcare (NASDAQ:ACHC) announced its earnings results on Tuesday. The company reported $0.38 earnings per share for the quarter, beating analysts’ consensus estimates of $0.35 by $0.03, Zacks reports. The business had revenue of $865.84 million during the quarter, compared to analyst estimates of $844.19 million. Acadia Healthcare had a negative net margin of 32.84% and a positive return on equity of 7.09%. The company’s quarterly revenue was down .4% compared to the same quarter last year. During the same period in the previous year, the business earned $0.83 EPS. Acadia Healthcare updated its FY 2026 guidance to 1.450-1.600 EPS.

Acadia Healthcare Price Performance

NASDAQ:ACHC opened at $32.69 on Wednesday. The business’s 50-day simple moving average is $27.94 and its two-hundred day simple moving average is $23.50. Acadia Healthcare has a 52 week low of $11.43 and a 52 week high of $35.83. The stock has a market cap of $3.01 billion, a PE ratio of -2.67, a P/E/G ratio of 10.84 and a beta of 0.64. The company has a quick ratio of 1.71, a current ratio of 1.71 and a debt-to-equity ratio of 1.27.

Key Stories Impacting Acadia Healthcare

Here are the key news stories impacting Acadia Healthcare this week:

• Positive Sentiment: Acadia reported second-quarter revenue of $865.8 million, exceeding the approximately $844 million analyst consensus. Adjusted earnings were $0.38 per share, ahead of estimates ranging from $0.33 to $0.35. Management said revenue growth was 2.8% after normalizing for prior-period supplemental-payment revenue. Acadia Healthcare Second-Quarter Results
• Positive Sentiment: The company updated its full-year 2026 outlook, calling for EPS of $1.45 to $1.60 and revenue of $3.4 billion to $3.5 billion. The guidance and operating trends appear to have reassured investors despite largely flat reported year-over-year revenue. 2026 Guidance Update
• Positive Sentiment: UBS analyst A.J. Rice reiterated a Buy rating and maintained a $39 price target, citing solid operating trends and the updated 2026 guidance. The target implies continued upside from recent trading levels. UBS Rating Update
• Neutral Sentiment: The earnings beat was tempered by weaker profitability: quarterly EPS declined from $0.83 a year earlier, while reported revenue was approximately flat year over year. Investors will likely focus on whether normalized growth can translate into sustained earnings improvement. Acadia Q2 Earnings Beat
• Negative Sentiment: A securities class-action lawsuit against Acadia can proceed after a court denied the company’s motion to dismiss. The ruling does not establish liability, but the litigation could create legal costs, reputational risk, and uncertainty for shareholders. Acadia Securities Litigation

Institutional Trading of Acadia Healthcare

Several institutional investors and hedge funds have recently added to or reduced their stakes in ACHC. Invesco Ltd. grew its holdings in Acadia Healthcare by 58.7% during the 4th quarter. Invesco Ltd. now owns 727,846 shares of the company’s stock valued at $10,328,000 after buying an additional 269,140 shares in the last quarter. Wellington Management Group LLP lifted its holdings in shares of Acadia Healthcare by 24.9% in the fourth quarter. Wellington Management Group LLP now owns 11,774,308 shares of the company’s stock worth $167,077,000 after buying an additional 2,350,760 shares in the last quarter. SummitTX Capital L.P. bought a new position in shares of Acadia Healthcare during the fourth quarter worth $821,000. Toronto Dominion Bank bought a new stake in Acadia Healthcare in the 4th quarter valued at $5,880,000. Finally, Twinbeech Capital LP purchased a new stake in Acadia Healthcare in the 4th quarter worth $1,182,000.

Analyst Upgrades and Downgrades

ACHC has been the subject of a number of research reports. Guggenheim upped their price objective on Acadia Healthcare from $26.00 to $31.00 and gave the company a “buy” rating in a research report on Monday, May 4th. KeyCorp upped their price target on shares of Acadia Healthcare from $30.00 to $40.00 and gave the company an “overweight” rating in a research report on Tuesday, July 14th. UBS Group raised their price objective on shares of Acadia Healthcare from $31.00 to $39.00 and gave the stock a “buy” rating in a report on Thursday, July 9th. Royal Bank Of Canada upped their target price on shares of Acadia Healthcare from $28.00 to $31.00 and gave the company an “outperform” rating in a report on Monday, May 4th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Acadia Healthcare in a research report on Friday, June 12th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $28.69.

About Acadia Healthcare

Acadia Healthcare Company, Inc (NASDAQ: ACHC) is a publicly traded provider of behavioral healthcare services headquartered in Franklin, Tennessee. Founded in 2005, the company has grown through organic expansion and strategic acquisitions to establish itself as a leading specialist in mental health and addiction treatment across the United States.

Acadia operates a diversified network of inpatient psychiatric hospitals, residential treatment centers, outpatient clinics and intensive outpatient programs.